BRCA1 and neoplasm: Azim et al. (24) discovered that patients aged ≤ 40 years had a higher expression of RANK-ligand, c-kit, mammary stem cell markers, luminal progenitor markers, and BRCA1 mutation signatures, independent of tumor subtype, grade, and stage.